Cellular Biomedicine Group Reports Full-Year and Fourth

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cellular Biomedicine Group Reports Full-Year and Fourth Quarter 2014 Financial Results

SHANGHAI, China and PALO ALTO, Calif., March 31, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq: CBMG ) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today reported full-year and fourth quarter 2014 financial results for the period ended December 31, 2014.

"2014 laid the foundation for building a world-class biotechnology enterprise that was marked by achieving notable corporate and clinical milestones and meaningful acquisitions that will drive our business momentum as we move into 2015," said William (Wei) Cao, PhD, BM, Chief Executive Officer of Cellular Biomedicine Group. "In addition to our successful listing on NASDAQ, we accelerated the growth of our Immuno-Oncology platform through the acquisition of Agreen Biotech Co. Ltd. China ("AG"), the acquisition of third generation Chimeric Antigen Receptor T cell (CAR-T), anti-PD-1, CD19 and aAPC cancer immunotherapy technologies from Persongen Biotechnology Ltd., and the acquisition of four CAR-T therapies with corresponding Phase I clinical data and manufacturing knowledge from Chinese PLA General Hospital ("PLAGH", Beijing, also known as "301 Hospital"). The Company's lead product candidate from our Human Adipose-Derived Mesenchymal Progenitor Cell (haMPC) Platform, ReJoin TM for the treatment of Knee Osteoarthritis (KOA), reported positive 12 month results from its Phase IIa clinical trials in 2014 and we are encouraged by the interim Phase IIb clinical data released in the first quarter of 2015 which continues to show excellent progress. We look forward to 2015 as we continue to amalgamate novel cancer technology leaders, deliver promise from our clinical trials to serve several large unmet medical needs in China and seek to evolve into a leader in the biotechnology field."

Tony (Bizuo) Liu, Chief Financial Officer of the Company, commented, "I am pleased to also announce the successful completion of an $18 million private placement transaction in 2014 and $20 million in 2015 which fortified our cash position. We will continue to leverage our financial resources to expand our technology portfolio, strengthen our clinical pipeline, pursue strategic acquisitions, add world-class scientific talent and evaluate multi-national licensing opportunities. We believe these strategic initiatives will further validate our vision of becoming an innovative cell-therapy company that delivers value to our shareholders."

Corporate and Clinical Developments of 2014 and Early 2015

During 2014 and 2015 to date, Cellular Biomedicine Group achieved the following milestones and significant corporate events:

Clinical Developments

1. Announced positive clinical data from Phase I of its CAR-T immuno-oncology clinical development programs of CAR-T CD19 for Acute Lymphocytic Leukemia (B-cell ALL) and CAR-T CD20 for Advanced Diffuse Large B Cell Lymphoma (DLBCL)

2. Launched a clinical study on human adipose derived mesenchymal progenitor cell (haMPC) therapy for Cartilage Damage (CD) resulting from osteoarthritis (OA) or sports injury, which study also serves as a supporting study of ReJoin TM for Knee Osteoarthritis (KOA)

3. Released positive 12-month follow-up data analysis of Phase I/IIa clinical trial for ReJoin TM  human adipose-derived mesenchymal progenitor cell (haMPC) therapy for KOA

4. Announced positive interim 24-week clinical data from the Phase IIb trial of its ReJoin TM  haMPC therapy for KOA

Corporate Developments

5. The Company successfully listed onto Nasdaq Capital Markets as the first pure-play cell therapy company from China

6. Closed private placement transactions for total gross proceeds of approximately $38 Million

7. Expanded Intellectual Property portfolio to 69 patents in various stages of approval in China, U.S. and through the Patent Cooperation Treaty (PCT), including one granted US Patent and 15 granted China patents

Fourth Quarter and 2014 Financial Performance

1. Cash Position:  Cash and liabilities at December 31, 2014 of approximately $14.8 million and $4.5 million, respectively. (Subsequently, in March 2015, the Company closed a private placement transaction for total gross proceeds of approximately $20,000,000)

2. Net Cash Used in Operating Activities :  Q4 and full-year 2014 operating cash burn of $2.2 million and $10.3 million, respectively, compared to $1.3 million and $8.5 million for the same periods in 2013

3. Revenue:  Q4 and full-year 2014 revenue of $0.4 million and $0.6 million, respectively, compared to $0.1 million and $0.2 million for the same periods in 2013

4. G&A Expenses:  Q4 and full-year 2014 general and administrative expenses of $3.3 million and $8.4 million, respectively, compared to $2.2 million and $9.3 million for the same periods in 2013. Excluding the stock-based compensation of $1.9 million and $1.5 million recorded in G&A expenses for full-year 2014 and 2013, the G&A expenses would have been $6.5 million and $7.8 respectively.

5. R&D Expenses:  Q4 and full-year 2014 research and development expenses of $0.8 million and $2.7 million, respectively, compared to $0.6 million and $1.9 million for the same periods a year ago, the increase mainly attributable to significant activities surrounding the development of our biomedicine intellectual property, including the implementation of Phase IIb clinical trials for KOA and launch of the clinical trial for cartilage damage

6. Net Loss:  Q4 and full-year 2014 net loss allocable to common stock holders was $5.5 million and $15.5 million, respectively, compared to $6.5 million and $13.8 million for the same periods in 2013. Excluding the stock-based compensation of $1.9 million and $1.5 million recorded for full-year 2014 and 2013, the net loss would have been $13.6 million and $12.3 million respectively.

Primary 2015 Operating Objectives:

1. Publish CAR-T Phase I Clinical Data of CD30 for Hodgkin's lymphoma and EGFR (HER1) for advanced lung cancer

2. Initiate CAR-T Phase II Clinical Trials of CD19, CD20, CD30 and EGFR (HER1)

3. Expand GMP facilities to 47,000 ft 2

4. Release 48-week follow-up data from ReJoin TM Phase IIb Clinical Trial

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers.  Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit: www.cellbiomedgroup.com .

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

CELLULAR BIOMEDICINE GROUP, INC.
(FORMERLY EASTBRIDGE INVESTMENT GROUP CORPORATION)
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
     
     
  For the Year Ended
  December 31,
  2014 2013
     
Net sales and revenue $564,377 $204,914
     
Operating expenses:    
Cost of sales 213,243 296,212
General and administrative 8,413,251 9,314,143
Selling and marketing 280,595 57,670
Research and development 2,671,932 1,890,506
Other general expenses 1,427,840 --
Total operating expenses 13,006,861 11,558,531
Operating loss (12,442,484) (11,353,617)
     
Other income (expense):    
Interest income 15,043 1,294
Other income (expense) 71,982 (6,196)
Total other income (expense) 87,025 (4,902)
Loss from continuing operations before taxes (12,355,459) (11,358,519)
     
Income tax provision -- --
     
Loss from continuing operations (12,355,459) (11,358,519)
     
Loss on discontinued operations, net of tax (3,119,152) (2,438,514)
     
Net loss $(15,474,611) $(13,797,033)
Other comprehensive income (loss):    
Cumulative translation adjustment 15,254 78,650
Unrecognized gain (loss) on investments 1,611,045 (198,200)
Total other comprehensive income (loss): 1,626,299 (119,550)
     
Comprehensive loss $(13,848,312) $(13,916,583)
     
Earnings (loss) per share for continuing operations:    
Basic $(1.43) $(1.96)
Diluted $(1.43) $(1.96)
     
Earnings (loss) per share discontinued operations:    
Basic $(0.36) $(0.42)
Diluted $(0.36) $(0.42)
     
Earnings (loss) per share net loss:    
Basic $(1.79) $(2.38)
Diluted $(1.79) $(2.38)
     
Weighted average common shares outstanding:    
Basic 8,627,094 5,792,888
Diluted 8,627,094 5,792,888
 
CELLULAR BIOMEDICINE GROUP, INC.
(FORMERLY EASTBRIDGE INVESTMENT GROUP CORPORATION)
CONSOLIDATED BALANCE SHEETS
     
  December 31, December 31,
  2014 2013
     
Assets    
Cash and cash equivalents $14,770,584 $7,175,215
Accounts receivable 141,029 10,581
Other receivable 135,957 78,521
Inventory 372,249 119,119
Prepaid expenses 565,299 56,911
Other current assets 110,347 134,661
Total current assets 16,095,465 7,575,008
     
Investments 6,886,033 5,105,891
Property, plant and equipment, net 1,280,410 1,014,805
Goodwill 7,678,789 3,299,566
Intangibles, net 11,156,676 601,456
Long-term prepaid expenses and other assets 587,729 --
Total assets $43,685,102 $17,596,726
     
Liabilities and Stockholders' Equity    
     
Liabilities:    
Accounts payable $426,917 $213,891
Accrued expenses 2,074,384 503,717
Tax payable 814,288 1,164,747
Advances payable to related party 36,254 67,999
Other current liabilities 724,479 251,299
Total current liabilities 4,076,322 2,201,653
     
Other non-current liabilities 452,689 --
Total liabilities 4,529,011 2,201,653
     
Commitments and Contingencies    
     
Stockholders' equity:    
     
Preferred stock, par value $.001, 50,000,000 shares    
authorized; none issued and outstanding as of    
December 31, 2014 and 2013, respectively -- --
     
Common stock, par value $.001, 300,000,000 shares authorized;    
10,990,335 and 7,382,797 issued and outstanding    
as of December 31, 2014 and 2013, respectively 10,990 7,383
Additional paid in capital 75,467,316 37,861,593
Accumulated deficit (37,890,590) (22,415,979)
Accumulated other comprehensive income (loss) 1,568,375 (57,924)
Total stockholders' equity 39,156,091 15,395,073
     
Total liabilities and stockholders' equity $43,685,102 $17,596,726
     
     
CELLULAR BIOMEDICINE GROUP, INC.
(FORMERLY EASTBRIDGE INVESTMENT GROUP CORPORATION)
CONSOLIDATED STATEMENTS OF CASH FLOWS
     
  For the Year Ended
  December 31,
  2014 2013
     
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $(15,474,611) $(13,797,033)
Adjustments to reconcile net loss to net cash    
used in operating activities:    
Depreciation and amortization 1,190,505 841,235
Loss on disposal of assets 257,672 --
Stock based compensation expense 1,949,908 4,381,077
Other than temporary impairment 1,427,840 --
Impairment of goodwill 3,299,566 4,258,967
Third party services received in exchange for disposition of investment stock -- 83,334
Loss recognized in excess of cash received on disposition of investment stock 5,913 138,909
Value of stock received for services (1,610,000) (3,500,000)
Deferred tax -- (76,544)
Changes in operating assets and liabilities:    
Accounts receivable 20,645 10,102
Other receivable (25,638) 50,160
Inventory (78,310) (81,878)
Prepaid expenses (494,057) (38,793)
Other current assets 24,314 (84,661)
Investments 7,150 --
Long-term prepaid expenses and other assets (504,678) 134,229
Accounts payable 165,517 40,862
Accrued expenses 409,109 (739,839)
Other current liabilities (694,131) 186,464
Taxes payable (176,583) (10,121)
Deferred revenue -- (251,834)
Net cash used in operating activities (10,299,869) (8,455,364)
     
CASH FLOWS FROM INVESTING ACTIVITIES:    
Acquisition of business, net of cash acquired (1,485,548) --
Purchases of intangibles (8,989) (5,828)
Purchases of assets (311,625) (147,211)
Net cash used in investing activities (1,806,162) (153,039)
     
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from the issuance of common stock 19,700,933 11,561,386
Proceeds from exercise of stock options 19,383 --
Repayment of advances from affiliate (31,745) (1,250)
Advances from affiliate -- 36,614
Net cash provided by financing activities 19,688,571 11,596,750
     
EFFECT OF EXCHANGE RATE CHANGES ON CASH 12,829 41,972
     
INCREASE IN CASH AND CASH EQUIVALENTS 7,595,369 3,030,319
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 7,175,215 4,144,896
CASH AND CASH EQUIVALENTS, END OF PERIOD $14,770,584 $7,175,215
     
SUPPLEMENTAL CASH FLOW INFORMATION    
     
Cash paid for income taxes $460,924 $--
Non cash financing and investing activities:    
Issuance of company stock for accrued liabilities and advances $-- $149,475
Issuance of company stock for acquisition of patent $1,442,850 $--
Issuance of company stock for acquisition of business $14,496,256 $--

Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 Vivian Chen Managing Director Investor Relations, Grayling +1 347-481-3711

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 126

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 117

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 156

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 94

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

NewRiver REIT Announces Scrip Dividend Reference Price

Updated Category News Views 335

NewRiver REIT's Scrip Dividend Reference Price Announcement NewRiver REIT plc has made a significant announcement regarding the reference price for its scrip dividend option, which is tied to its interim dividend. This dividend pertains to the six-month period ending on September 30, 2024. Understanding the Scrip Dividend Option The reference price has been set at 73.41...

Continue Reading
Upcoming Shareholders' Meeting Announcement for Siguldas CMAS

Updated Category News Views 200

Important Shareholders' Meeting Information The Management Board of Joint Stock Company ‘Siguldas ciltslietu un m?ksl?g?s aps?klošanas stacija’ is excited to announce an important shareholders' meeting for the company. This meeting is a key opportunity for all shareholders to engage in discussions concerning the company's future. Meeting Details Scheduled for April...

Continue Reading
Empowering Women in Finance: Insights from Cboe Leaders

Updated Category News Views 168

Empowering Women in Finance In a recent dialogue, Cathy Clay, Executive Vice President and Global Head of Derivatives at Cboe, along with Meghan Dugan, Senior Vice President overseeing U.S. Options, and Alexandra Szakats, Vice President and Head of The Options Institute, shared their journeys and advice regarding their roles as leaders in the options industry. These women...

Continue Reading
Bird Dog Whiskey Debuts Premium Kentucky Straight Bourbon

Updated Category News Views 220

Bird Dog Whiskey Unveils Select Reserve Kentucky Straight Bourbon Bird Dog Whiskey has exciting news for bourbon enthusiasts. The brand has launched a highly anticipated addition to its lineup: the Select Reserve Kentucky Straight Bourbon Whiskey. This new offering is set to capture the hearts of loyal fans. A Smooth and Rich Bourbon Experience At 86 proof, Bird Dog...

Continue Reading
Vera Therapeutics Announced Key Stock Option Grants for New Hires

Updated Category News Views 160

Introduction to Vera Therapeutics' Inducement Awards Vera Therapeutics, Inc. (Nasdaq: VERA) has proudly announced a significant step in its commitment to fostering talent by granting inducement awards to new employees. On a recent date, the Compensation Committee approved these awards, which included stock options and restricted stock units (RSUs) to reward and attract...

Continue Reading